Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference23 articles.
1. Efficacy and safety of Hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency;Borte;J. Clin. Immunol.,2011
2. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home;Gardulf;J. Allergy Clin. Immunol.,2004
3. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency;Berger;Immunol. Allergy Clin. North Am.,2008
4. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease;Jolles;Clin. Exp. Immunol.,2015
5. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency;Wasserman;Clin. Pharmacokinet.,2011
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies;International Immunopharmacology;2022-12
2. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies;Clinical and Experimental Immunology;2022-10-08
3. Passive immunization against COVID-19 by anti-SARS-CoV-2 spike IgG in commercially available immunoglobulin preparations in severe antibody deficiency;The Journal of Allergy and Clinical Immunology: In Practice;2022-09
4. Physiological based pharmacokinetic and biopharmaceutics modelling of subcutaneously administered compounds – An overview of in silico models;International Journal of Pharmaceutics;2022-06
5. High-dose immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis;eNeurologicalSci;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3